

NNDSS – Influenza subtyping for 2017

Туре	2014	2015	2016 %	2017 %	2017 WHO CC
A(H1N1)pdm	11	2	6	1	14
A(H3N2)	8	7	11	4	63
A (untyped)	70	29	73	57	-
В	11	61	10	37	23






NNDSS Laboratory confirmed influenza cases by age 2016





WHO Collaborating Centre for Reference and Research on Influenza VIDRL


ILI in NZ in 2017







FluCAN hospitalisation data




Age y	# hosp	%	Direct to ICU
0-15	572	14	?
16-64	1314	33	11.9
65+	2071	52	8.3

A(unsubtyped)

A(H3N2)

Patients admitted directly to ICU -

- A(H1N1)pdm09 15.8%
- A(H3N2) 8.6%
- influenza B 8.5%.



Month and week of admission



AUSTRALIAN INFLUENZA SURVEILLANCE REPORT

> No. 12, 2017 14 – 27 October 2017

Reported influenza outbreaks in NSW institutions

(up to Nov 2107)

Year	2010	2011	2012	2013	2014	2015	2016	2017*
No. of outbreaks	2	4	39	12	120	103	279	588






Nationally Notified Influenza Associated Deaths

(Aust. Influenza Report)

Year	Deaths #	Median age y	Virus type/subtype
2011	14	47	83% A(H1N1)pdm
2012	60	78	88% A(H3N2)
2013	28	63	86% Influenza A
2014	72	72	100% Influenza A
2015	97	85	B and A(H3N2)
2016	92	80	87% Influenza A
2017	598	85	78% influenza A

ating Centre

Rate of deaths classified as influenza and pneumonia per 100 000 NSW population, 2012 – 2017





Vaccine effectiveness for Australia 2017 - Overall

RAPID COMMUNICATIONS

Eurosurveillance October 26 2017

Low interim influenza vaccine effectiveness, Australia, 1 May to 24 September 2017

Sheena G Sullivan^{1,2,3}, Monique B Chilver³, Kylie S Carville⁴, Yi-Mo Deng¹, Kristina A Grant⁴, Geoff Higgins⁵, Naomi Komadina¹, Vivian KY Leung¹, Cara A Minney-Smith⁶, Don Teng⁷, Thomas Tran⁴, Nigel Stocks³, James E Fielding^{2,4}

Type/subtype	A co croup	Cases				Controls				Adjusted ^a VE
	Age group	Unvaccinated		Vaccinated		Unvaccinated		Vaccinated		(95% CI)
A or B	All ages	772	73%	288	27%	802	63%	477	37%	33% (17 to 46)
	Children (15y	235	94%	14	6%	179	94%	12	6%	16% (-95 to 63)
	Adults 15-64y	512	74%	181	26%	587	65%	322	35%	39% (24 to 51)
	Adults ≥65y	25	21%	93	79%	36	20%	143	80%	-3% (-92 to 44)



Vaccine effectiveness for Australia 2017 - By type/subtype/lineage

Tuno/cubtuno	A minutes		Case	es			Contr	Adjusted ^a VE		
Type/subtype	Age group	Unva	ccinated	Vacc	inated	Unvac	ccinated	Vac	cinated	(95% CI)
1.0	All ages	74	84%	14	16%	802	63%	477	37%	50% (8 to 74)
A/Us)ndmon	Children < 15y	33	97%	1	3%	179	94%	12	6%	NE
A(H1)pdmo9	Adults 15-64y	40	78%	11	22%	587	65%	322	35%	49% (2 to 76)
	Adults≥65y	1	33%	2	67%	36	20%	143	80%	NE
	All ages	347	66%	175	34%	802	63%	477	37%	10% (-16 to 31)
	Children < 15y	100	94%	6	6%	179	94%	12	6%	17% (-132 to73)
A(H ₃)	Adults 15-64y	233	68%	110	32%	587	65%	322	35%	16% (-11 to 36)
	Adults≥65y	14	19%	59	81%	36	20%	143	80%	-20% (-160 to 42)
	All ages	306	82%	69	18%	802	63%	477	37%	57% (41 to 69)
	Children (15y	91	96%	4	4%	179	94%	12	6%	NE
В	Adults 15-64y	208	82%	45	18%	587	65%	322	35%	63% (48 to 74)
	Adults≥65y	7	26%	20	74%	36	20%	143	80%	10% (-156 to 65)
	All ages	11	100%	0	0%	802	63%	477	37%	NE
D/Mi-tonia	Children < 15y	4	100%	0	0%	179	94%	12	6%	NE
B/Victoria	Adults 15-64y	7	100%	0	0%	587	65%	322	35%	NE
	Adults≥65y	0	NA	0	NA	36	20%	143	80%	NE
	All ages	206	80%	53	20%	802	63%	477	37%	45% (22 to 62)
200	Children < 15y	71	96%	3	4%	179	94%	12	6%	NE
B/Yamagata —	Adults 15-649	130	77%	38	23%	587	65%	322	35%	49% (26 to 66)
	Adults≥65y	5	29%	12	71%	36	20%	143	80%	27% (-162 to 77)

VIDKL

Influenza vaccines for Australia and NZ in 2018

- H1N1pdm A/Michigan/45/2014-like
- H3 A/Singapore/INFIMH-16-0019/2016-like

Trivalent vaccine:

B – B/Phuket/3073/2013-like (B/Yam)

Quadrivalent vaccine:

- B B/Phuket/3073/2013-like (B/Yam)
- B B/Brisbane/60/2008-like (B/Vic)


*Changes to 2017 recommendations



The NH 2017-8 influenza season (so far)



"Aussie Flu" hits UK as at 22 Jan 2018









WHO Collaborating Centre for Reference and Research on Influenza VIDRL


Influenza in Europe



Data from EU and EEA countries for the 2017–18 season Week 4 (22–28 January 2018)


Influenza viruses circulating in 2017-2018

Only sentinel specimens are included




Influenza intensity in week 4

based on sentinel reports of influenza-like illness and/or acute respiratory infections



Bubble size is indicative of country population






10 Collaborating Centre Reference and search on Influenza




A Weekly Influenza Surveillance Report Prepared by the Influenza Division

Percentage of Visits for Influenza-like Illness (ILI) Reported by the U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet), Weekly National Summary, 2017-2018 and Selected Previous Seasons



Fluview: Influenza in the USA as at Feb 1 2018












A Weekly Influenza Surveillance Report Prepared by the Influenza Division


Influenza Positive Tests Reported to CDC by U.S. Public Health Laboratories, National Summary, 2017-2018 Season





A Weekly Influenza Surveillance Report Prepared by the Influenza Division


Pneumonia and Influenza Mortality from the National Center for Health Statistics Mortality Surveillance System Data through the week ending January 13, 2018, as of February 1, 2018





A Weekly Influenza Surveillance Report Prepared by the Influenza Division

Number of Influenza-Associated Pediatric Deaths by Week of Death: 2014-2015 season to present






A Weekly Influenza Surveillance Report Prepared by the Influenza Division

Laboratory-Confirmed Influenza Hospitalizations

Preliminary cumulative rates as of Jan 27, 2018





Summary of influenza seasons

- Mega season in Australia (highest on record by NNDSS) with exception of WA!
- Low season in NZ; LC ILI activity just above season baseline (40 cases/100,000 population)
- Influenza H3 predominant in Aus + NZ
- B-Yamagata lineage predominated in Australia (10:1 Yam:Vic) & NZ
- Vaccine match good for H1N1pdm and B's, A(H3N2) poor
- Very few oseltamivir resistant viruses detected
- Hospital admissions & deaths in Australia both high
- Australian Vaccine Effectiveness: INTERIM data 33% overall but only 10% for H3N2
- H3N2 component of the Australian/NZ 2018 vaccine updated from 2017
- Influenza activity 2017-8 in Nth Hemisphere; high in USA, moderate in EU
- A(H3N2) the predominant virus in USA, B's in Europe/China, H1N1pdm in Japan
- Why was 2017 such a big year? \$64M question; Low population immunity (H3 2012/4/6). Poor vaccine performance of H3 (egg adaptions), Number of H3 variants co-circulating????
- Prediction for 2018; A quiet year with B's and H1N1pdm's predominating!!



Acknowledgments

- Various influenza reports
 - Australian influenza surveillance report
 - NSW Influenza report
 - ESR Influenza weekly update
 - CDC Fluview
 - ECDC
 - WHO reports
- NICs and labs that have sent us samples
- Staff at Melbourne WHO CC
- Sheena Sullivan for VE data
- Other WHO CC's especially CNIC for zoonotic reports
- WPRO and WHO HQ Geneva



Possible ways to improve Australia's response to influenza epidemics (especially A(H3N2)-driven ones) ROUND TABLE DISCUSSION

1. Vaccine improvements – targeting of susceptible/at risk groups

- a. High dose or adjuvanted vaccines especially for the elderly (or focus on nursing home residents)
- b. LAIV for school aged children (similar to the current UK system), or free IIV like WA & QLD
- c. Non-egg based vaccines; Protein sciences rHA, cell-based vaccines, recombinant proteins, VLP's etc
- d. Mandatory vaccination for HCW and nursing home staff, carers etc
- e. Wider use of pneumococcal vaccines in adults not just elderly
- f. Free vaccine for everyone!!

2. Antiviral drug use/availability

- a. Neuraminidase inhibitors available OTC as is the case in NZ during the flu season
- b. Better use of Government stockpiles when NI's are in short supply eg 2017
- c. Mandatory stocking of nursing homes with NI and training of staff in how/when to use them

3. Public Health measures

- a. Appoint Robert Booy as minister for influenza prevention
- b. Run TV advertisements/social media campaigns on getting vaccinated, issues/advantages, pregnancy etc.
- c. Improving flu' etiquette amongst the public by public awareness campaigns; eg. staying home if infected, not coughing or sneezing on others, not shaking hands and regular hand washing by everyone
- d. Use of masks, cancelling major events, closing schools or day-care centres during peak activity
- e. Change the vaccine recommendations to everyone above 6 months of age (like the USA)
- f. Increased rapid diagnostic testing for influenza; place in all nursing homes, home testing, other sites?

4. Research

- a. More research/funding on Universal influenza vaccine development
- b. Federal Gov. to fund cost/benefit studies on use of "new" vaccines in elderly/institutionalized
- c. Have an NHMRC special fund for ideas that address the issue eg like 2009 H1pdm09 research funding

5. Other

- a. ???
- b. ???
- c. ???